Corcept Therapeutics (CORT) Misses Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 --0%
Revenue Growth %: +54.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +54.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $10.5 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- Morgan Stanley Upgrades M&T Bank (MTB) to Overweight
- Erste Group Starts Marsh (MRSH) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
